Skip to main content

Table 4 Promoter methylation in NSCLC-univariate associations with clinicopathologic characteristics (OR and 95% CI)

From: Association of promoter methylation with histologic type and pleural indentation in non-small cell lung cancer (NSCLC)

Genes Male vs. Female Age (per 10 years) Smoking history Pack-years1 SCC vs. ADC
CALCA 0.73 (0.28-1.90) 0.94 (0.58-1.52) 1.43 (0.57-3.57) 0.88 (0.51-1.51) 2.21 (0.89-5.47)
CDH1 2.13 (0.86-5.22) 0.83 (0.53-1.30) 1.41 (0.59-3.39) 0.91 (0.55-1.50) 2.63 (1.05-6.60)*
DAPK1 1.45 (0.43-4.87) 1.16 (0.60-2.24) 2.11 (0.64-6.92) 1.83 (0.84-3.98) 6.64 (1.85-23.8)*
IRX2 1.29 (0.54-3.06) 0.76 (0.48-1.19) 1.06 (0.45-2.52) 0.91 (0.55-1.50) 2.89 (1.17-7.13)*
TIMP3 1.09 (0.46-2.60) 1.09 (0.70-1.71) 1.09 (0.46-2.60) 1.27 (0.76-2.11) 2.51 (1.01-6.21)*
PAX6 1.04 (0.37-2.88) 1.19 (0.70-2.03) 0.78 (0.27-2.25) 0.93 (0.51-1.69) 1.04 (0.37-2.88)
Genes Tumor size 2 Lymph node metastasis Pleural indentation Invasion or Adhesion Histologic stage 3
CALCA 1.01 (0.55-1.88) 1.74 (0.62-4.91) 1.18 (0.41-3.41) 2.44 (0.88-6.79) 2.13 (1.01-4.47)*
CDH1 1.20 (0.67-2.13) 1.02 (0.41-2.51) 1.79 (0.67-4.76) 0.96 (0.41-2.27) 1.11 (0.62-2.02)
DAPK1 1.81 (0.72-4.54) 5.17 (0.64-41.95) 1.63 (0.33-8.02) 1.70 (0.43-6.67) 1.24 (0.50-3.08)
IRX2 1.57 (0.88-2.83) 1.17 (0.47-2.88) 1.37 (0.52-3.63) 0.86 (0.36-2.01) 1.14 (0.63-2.07)
TIMP3 1.67 (0.92-3.01) 2.05 (0.82-5.10) 1.16 (0.44-3.05) 0.69 (0.29-1.66) 1.88 (1.01-3.49)*
PAX6 0.78 (0.40-1.54) 0.74 (0.26-2.09) 2.04 (0.54-7.69) 1.84 (0.61-5.56) 1.76 (0.79-3.93)
  1. † OR: odds ratio with 95% confidence interval.
  2. 1 Pack-years (0; > 0 and < 40; ≥ 40).
  3. 2 Tumor size (> 1 and ≤3; > 3 and ≤5; > 5).
  4. 3 Histologic stage (I; II; III).
  5. * Significant at P < 0.05.